Cytosorbents corp (CTSO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash flows from operating activities:
Net loss

-19,265

-17,211

-8,460

-11,763

-9,477

-9,321

-4,677

-3,663

-5,481

Adjustments to reconcile net loss to net cash used by operating activities:
Contributed technology expense

-

-

-

-

-

-

-

0

0

Consulting expense

-

-

-

-

-

-

-

0

0

Management unit expense

-

-

-

-

-

-

-

0

0

Expense for issuance of warrants

-

-

-

-

-

-

-

0

0

Expense for issuance of options

-

-

-

-

-

-

-

63

865

Amortization of deferred compensation

-

-

-

-

-

-

-

0

0

Non-cash interest expense

0

637

0

0

-

-

-

0

0

Common stock issued as inducement to convert convertible notes payable and accrued interest

-

-

-

-

-

-

-

0

0

Non-cash compensation

1,173

947

691

431

-

180

65

0

0

Depreciation and amortization

581

390

218

161

112

65

64

54

39

Amortization of debt costs

-

-

-

-

-

198

311

471

945

Gain on disposal of property and equipment

-

-

-

-

-

-

-

0

0

Gain on extinguishment of debt

-

-

-

-

-

-

-

0

0

Interest expense paid with Series B Preferred Stock in connection with conversion of notes payable

-

-

-

-

-

-

-

0

0

Abandoned patents

-

-

-

-

-

-

-

-

0

Abandoned patents

-

-

-

-

-

-

-

0

-

Bad debt

72

14

0

65

0

4

0

0

0

Stock-based compensation

1,666

4,437

3,313

2,756

382

695

456

-

-

Change in warrant liability

-

-

-

-

-

2,118

0

-

-

Foreign currency transaction loss

-350

-784

1,454

-358

-386

-385

-

-

-

Amortization of loan acquisition costs

115

97

82

-

-

-

-

-

-

Amortization of loan acquisition costs

-

-

-

30

0

0

-

-

-

Changes in operating assets and liabilities:
Grants and accounts receivable

642

1,847

649

889

-131

412

401

15

36

Inventories

1,284

56

-57

-340

671

308

-436

251

431

Prepaid expenses and other current assets

953

731

76

-187

-178

108

129

432

-300

Other assets

-4

6

15

41

7

4

6

-9

0

Accounts payable and accrued expenses

1,424

1,704

-168

1,632

-83

497

118

147

-30

Accrued interest expense

-

-

-

-

-

-

-

0

0

Deferred revenue

-

-

-

-

-0

-271

272

0

-

Net cash used by operating activities

-

-

-

-

-

-6,280

-

-

-

Net cash used by operating activities

-16,758

-10,839

-6,460

-6,730

-9,047

-

-3,489

-3,616

-3,828

Cash flows from investing activities:
Proceeds from sale of property and equipment

-

-

-

-

-

-

-

0

0

Purchases of property and equipment

698

671

990

140

403

153

38

19

34

Payments for patent costs

821

848

687

454

239

214

177

18

17

Proceeds from sale of short-term investments

-

-

-

2,192

5,430

4,745

0

0

0

Purchases of short-term investments

-

-

-

-

5,678

6,689

0

0

-

Loan receivable

-

-

-

-

-

-

-

0

0

Net cash used by investing activities

-1,520

-1,520

-1,678

1,596

-890

-

-216

-38

-52

Cash flows from financing activities:
Net cash used by investing activities

-

-

-

-

-

-2,311

-

-

-

Proceeds from long-term debt

5,000

666

5,000

5,000

0

0

-

-

-

Repayment of long-term debt

0

666

0

0

-

-

-

-

-

Payment of loan acquisition costs

4

147

1

-

-

-

-

-

-

Payment of debt acquisition costs

-

-

-

118

0

0

-

-

-

Proceeds from issuance of preferred stock, net of related issuance costs

-

-

-

-

-

-

-

0

0

Equity contributions - net of fees incurred

673

14,126

13,679

0

9,524

9,751

2,199

3,500

2,756

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

0

Proceeds from borrowing

-

-

-

-

-

-

1,843

700

1,250

Proceeds from subscription receivables

-

-

-

-

-

-

-

0

0

Proceeds from exercise of stock options

739

2,206

591

118

410

109

20

10

5

Proceeds from exercise of warrants

1,768

1,280

853

65

1,705

156

139

0

-

Net cash provided by financing activities

-

-

-

-

-

10,016

-

-

-

Net cash provided by financing activities

8,177

17,465

20,123

5,064

11,640

-

4,202

4,210

4,012

Effect of exchange rates on cash

-35

-58

92

-1

9

-1

-43

-12

0

Net change in cash and cash equivalents

-10,136

5,046

12,076

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-71

1,711

1,422

453

542

130

Supplemental disclosure of cash flow information:
Cash paid during the period for interest

1,059

891

634

175

0

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

0

0

0

0

Supplemental disclosure of non-cash financing activities
Fair value of warrant liability upon issuance

-

-

-

-

-

862

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

0

-

-

Debt discount in connection with issuance of convertible debt

-

-

-

-

-

-

331

87

1,250

Settlement of accrued bonuses with restricted stock units

425

545

207

0

0

7

49

247

106

Note payable principal and interest conversion to equity

-

-

-

-

-

1,990

1,226

0

1,515

Issuance of member units

-

-

-

-

-

-

-

0

-

Issuance of management units in settlement of cost of raising capital

-

-

-

-

-

-

-

0

0

Change in fair value of management units for cost of raising capital

-

-

-

-

-

-

-

0

0

Issuance of common stock in exchange for stock subscribed

-

-

-

-

-

-

-

0

0

Costs paid from proceeds in conjunction with issuance of common stock

-

-

-

-

1,019

748

0

0

0

Dividend, warrant exercise price adjustment

0

0

335

0

0

-

-

-

-

Preferred stock dividends

-

-

-

-

-

9,266

2,395

2,511

3,087

Net effect of conversion of common stock to preferred stock prior to merger

-

-

-

-

-

-

-

0

0